Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : E-FoodSafety (EFSF) -- Ignore unavailable to you. Want to Upgrade?

To: strike_1 who wrote (5)	1/24/2006 12:07:23 AM
From: strike_1	Respond to of 47

EFSF: SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Jan. 23, 2006--Patricia Ross-Gruden, President and CEO of eFoodSafety.com, Inc. (OTCBB:EFSF), announced today that eFoodSafety.com, Inc. has been selected by The KonLin Letter as the .1 Stock Pick for 2006. The KonLin Letter reiterates its "Strong Buy" recommendation of EFSF stock. According to The KonLin Letter, eFoodSafety.com, Inc. has reorganized itself into a dynamo in less than a quarter, unlike any other low-priced stock followed in all of The KonLin Letter's history. The KonLin Letter, a 25-year-old investment advisory newsletter noted for its fundamental and technical analysis of individual stocks and market movements, does not accept compensation for its analyses of selected companies. The report includes a review of the latest developments of the Company, the Company's market position and potential advantages, along with fundamentals and statistics. Konrad Kuhn, publisher of The KonLin Letter, cited the following reasons for his 2006 recommendation on EFSF: -- Avian Influenza formulation for hard and porous surfaces has completed testing with 100% efficacy, while the Avian Influenza ingestible formula will soon undergo human clinical trials on Influenza Virus strains A & B - the Bush Administration in November 2005 proposed a $7.1 Billion budget to combat Avian Influenza in 2006 -- Anthrax Sporicidal is 100% effective on eradicating Anthrax's surrogate organisms, Bacillus Subtilis and Clostridium Sporogenes, on hard and porous surfaces and is expected to receive EPA approval in 2006 -- Cinnergen(TM)'s Direct Response Marketing Campaign is performing well with a National TV campaign underway within a $132 billion diabetes market -- Citroxin Cleaner was sold to aid and assist the clean-up in Louisiana, specifically to eradicate "black mold" in the Lake Charles, Louisiana area - EPA Registration on this product is anticipated shortly -- Talsyn(TM) CI/bid Scar Cream's sales are at pace with the Company's initial expectations capturing a share of the $4 billion scar cream market The KonLin Letter concurs with management that revenue growth should continue through the 3rd quarter ending January 31, 2006, while the 4th quarter ending April 30, 2006 should be when revenue growth begins to hit its stride. About KonLin Research & Analysis Corp. The KonLin Letter, www.KonLin.com, chooses low-priced stocks to analyze, with an emphasis on emerging growth and special situations poised for explosive price appreciation. The KonLin Letter has constantly been one of the leading publications on Wall Street. It has been rated one of the best performing market letters in the nation, offering a unique service that each month recommends five low-priced selections, including a featured stock of the month. EFSF was the featured stock in the month of September 2005. About eFoodSafety.com, Inc. eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.